Advertisement

Pharmaceutical Medicine

, Volume 32, Issue 1, pp 13–20 | Cite as

Development of Post-Marketing Risk Management Plan Requirements: The Singapore Experience

  • Liesbet Li-Bei Tan
  • Christine Su-Ching HoEmail author
  • Phey-Yen Han
  • Cheng-Leng Chan
Current Opinion
  • 94 Downloads

Abstract

Historically, global drug safety regulations were generally reactive and post-marketing safety monitoring comprised mainly spontaneous adverse event reporting. As a strategic move towards proactive pharmacovigilance, several drug regulatory agencies have introduced requirements for risk management plans (RMPs) since the early 2000s. The aim of this paper is to share the process on how the Health Sciences Authority (HSA), the national drug regulatory authority of Singapore, conceptualised and implemented its local RMP requirements, drawing upon the experiences of international regulatory agencies. Some of the steps taken include the incorporation of local RMP requirements into HSA’s guidance documents for the pharmaceutical industry, consultation with industry stakeholders on the proposed updates to these requirements, and strengthening of the enforcement of RMP requirements through relevant enactments in legislation. We also compared our requirements with that of other regulatory agencies to ensure that they were aligned with global regulatory standards. Based on our experience in developing the regulatory framework for RMP requirements in Singapore, we put forth recommendations which could be useful for other regulatory agencies embarking on the implementation of RMP requirements in their countries.

Notes

Acknowledgements

We thank Dr. Dorothy Toh for her support and guidance and Ms Jalene Poh and Ms Adena Lim for their advice regarding this manuscript.

Funding

No funding was received specifically for the publication of this article.

Compliance with Ethical Standards

Conflict of interest

Liesbet Li-Bei Tan, Christine Su-Ching Ho, Phey-Yen Han and Cheng-Leng Chan declare that they have no conflict of interest that is directly relevant to the content of this article. The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the Health Sciences Authority or any of its committees or working parties.

References

  1. 1.
    Mayall SJ, Banerjee AS. Therapeutic risk management of medicines. Cambridge, UK: Woodhead; 2014. pp. 25-59Google Scholar
  2. 2.
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline—Pharmacovigilance Planning E2E. 2004. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2E/Step4/E2E_Guideline.pdf. Accessed 14 Jun 2017.
  3. 3.
    Vermeer NS, Duijnhoven RG, Straus SM, Mantel-Teeuwisse AK, Arlett PR, Egberts AC, et al. Risk management plans as a tool for proactive pharmacovigilance: a cohort study of newly approved drugs in Europe. Clin Pharmacol Ther. 2014;96:723–31.CrossRefPubMedGoogle Scholar
  4. 4.
    US Food and Drug Administration. FDA Basics webinar: a brief overview of Risk Evaluation and Mitigation Strategies (REMS). 2012. http://www.fda.gov/downloads/AboutFDA/Transparency/Basics/UCM328784.pdf. Accessed 14 Jun 2017.
  5. 5.
    European Medicines Agency. Template for EU risk management plan (EU–RMP). 2006. http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2009/10/WC500006317.pdf. Accessed 14 Jun 2017.
  6. 6.
    European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module V—Risk management systems (Rev 2). 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/03/WC500224572.pdf. Accessed 14 Jun 2017.
  7. 7.
    US Food and Drug Administration. Risk evaluation and mitigation strategies template. 2009. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM188155.pdf. Accessed 14 Jun 2017.
  8. 8.
    Health Sciences Authority. Guidance on medicinal product registration in Singapore. Singapore: HSA; 2011.Google Scholar
  9. 9.
    European Medicines Agency. Guideline on risk management systems for medicinal products for human use. London: EMA; 2005.Google Scholar
  10. 10.
    European Medicines Agency. Guidelines on pharmacovigilance for medicinal products for human use (Volume 9A). 2008. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-9/pdf/vol9a_09-2008_en.pdf. Accessed 14 Jun 2017.  
  11. 11.
    Therapeutic Goods Administration. Risk management plans. 2015. https://www.tga.gov.au/book/export/html/4188. Accessed 14 Jun 2017.
  12. 12.
    Health Canada. Notice regarding implementation of risk management planning including the adoption of International Conference on Harmonisation (ICH) Guidance Pharmacovigilance Planning - ICH Topic E2E. 2009. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/product-vigilance/notice-regarding-implementation-risk-management-planning-including-adoption-international-conference-harmonisation-guidance-pharmacovigilance-planning.html. Accessed 14 Jun 2017.
  13. 13.
    Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. Risk Management Plan Guidance. 2012. https://www.pmda.go.jp/files/000153333.pdf. Accessed 14 Jun 2017.
  14. 14.
    Therapeutic Goods Administration. Risk management plans: Australian–specific annex template. 2017. https://www.tga.gov.au/book-page/australian-specific-annex-template. Accessed 14 Jun 2017.
  15. 15.
    Health Canada. Guidance document - Submission of risk management plans and follow–up commitments. 2015. https://www.canada.ca/en/health-canada/services/drugs-health-products/reports-publications/medeffect-canada/guidance-document-submission-risk-management-plans-follow-commitments.html. Accessed 14 Jun 2017
  16. 16.
    Health Sciences Authority. Guidance for Industry: Post-marketing vigilance requirements for therapeutic products. 2016. http://www.hsa.gov.sg/content/dam/HSA/HPRG/Safety_Alerts_Product_Recalls_Enforcement/Guidance%20for%20Industry_Post-marketing%20Vigilance%20Requirements%20for%20Therapeutic%20Products_Nov2016_v1revised.pdf. Accessed 14 Jun 2017.
  17. 17.
    Health Sciences Authority. Guidance for Industry: Post-marketing vigilance requirements for medicinal products. Singapore: HSA; 2015.Google Scholar
  18. 18.
    Health Sciences Authority. Guidance on medicinal product registration in Singapore—appendix: guideline on the submission of risk management plan documents. Singapore: HSA; 2015.Google Scholar
  19. 19.
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartitie Guideline—Periodic benefit-risk evaluation report (PBRER) E2C (R2). 2012. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2C/E2C_R2_Step4.pdf. Accessed 14 Jun 2017.
  20. 20.
    Attorney-General's Chambers. Singapore Statutes Online. Health Products Act (Chapter 122D)—Health Products (Therapeutic Products) Regulations 2016. 2016. https://sso.agc.gov.sg/SL/HPA2007-S329-2016?DocDate=20170509. Accessed 14 Jun 2017.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Vigilance and Compliance Branch, Health Products Regulation GroupHealth Sciences AuthoritySingaporeSingapore

Personalised recommendations